What Hospitalists Need to Know About Sickle Cell Disease

Additional information
Bibliography: 
  • Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., ... & Wang, S. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361(12), 1139-1151.
  • Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., ... & Becker, R. C. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine, 365(10), 883-891.
  • Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., ... & Bahit, M. C. (2011). Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 365(11), 981-992. 

You may also be interested in

Hematology Online Series (Multiple Modules)

This online series addresses multiple inpatient hematology topics and provides learners with the tools they need to triage and manage patients with these conditions to ensure better patient outcomes.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Speaker Credit™
Course opens: 
05/01/2018
Course expires: 
05/01/2020
Rating: 
0

Available Credit

  • 2.00 AMA PRA Category 1 Speaker Credit™

Accreditation Period

Course opens: 
05/01/2018
Course expires: 
05/01/2020
Please login or register to take this course.